Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.

Biochemical pharmacology - 1 Jun 2021

Chen Jian, Jia Xing, Li Zequn, Song Wenfeng, Jin Cheng, Zhou Mengqiao, Xie Haiyang, Zheng Shusen, Song Penghong

Abstract excerpt

Targeting the cell cycle checkpoints and DNA damage response are promising therapeutic strategies for cancer. Adavosertib is a potent inhibitor of WEE1 kinase, which plays a critical role in regulating cell cycle checkpoints. However, the effect of adavosertib on hepatocellular carcinoma (HCC) treatment, including sorafenib-resistant HCC, has not been thoroughly studied. In this study, we comprehensively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hep G2 Cells

Share to Mice, Nude

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyrimidinones

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 33684390
DOI: 10.1016/j.bcp.2021.114494

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.PMID 33684390Read ↗

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)Semantic proximity Read ↗

NOTCH1 regulates the DNA damage response and sorafenib resistance by activating ATM in hepatocellular carcinomaSemantic proximity Read ↗

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Semantic proximity Read ↗

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.Semantic proximity Read ↗

Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells.Semantic proximity Read ↗

Expression and Function Analysis of Mitotic Checkpoint Genes Identifies TTK as a Potential Therapeutic Target for Human Hepatocellular CarcinomaSemantic proximity Read ↗

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.Semantic proximity Read ↗

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read ↗

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Semantic proximity Read ↗

Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 InhibitionSemantic proximity Read ↗

BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.Semantic proximity Read ↗

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.